Andere talen Nova Mentis Life Science Corp.

Aandelen

NOVA

CA66980V1067

Beurs gesloten - Canadian Securities Exchange Andere beurzen 21:38:53 25-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
0,015 ^CAD	0,00%		+50,00%	-25,00%

08/04	Nova Mentis Life Science Corp. Rapporteert winstresultaten voor het volledige jaar dat eindigde op 31 december 2023	CI
26/02	Nova Mentis Life Science Corp. Kondigt de benoeming van Steve Loutskou tot lid van de Raad van Bestuur aan	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	08/04
Nova Mentis Life Science Corp. Announces the Appointment of Steve Loutskou to the Board of Directors	26/02
Nova Mentis Announces Change of Directors	26/02
Nova Mentis Life Science Corp. Announces Management Changes	04/01
Nova Mentis Life Science Corp. Announces Resignation of Dr. Stephen Glazer as Chief Scientific Officer and Director	11/12
Nova Mentis Life Science Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	29/11
Nova Mentis Life Science Corp.: Nova Mentis begrüßt Entscheidung der Regierung zur Einrichtung einer Beratergruppe für seltene Krankheiten	03/11
Nova Mentis Applauds Government Decision to Create Rare Disease Advisory Group	03/11
Nova Mentis Life Science Corp. - Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome	31-08-23
Nova Mentis Life Science Corp. Announces Participant Screening Underway in Canada's First Psilocybin Clinical Trial for Fragile X Syndrome	30-08-23
Nova Mentis Life Science Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	29-08-23
Nova Mentis Life Science Corp. Reports Earnings Results for the First Quarter Ended March 31, 2023	31-05-23
Nova Mentis Life Science Corp. Reports Earnings Results for the Full Year Ended December 31, 2022	25-04-23
Nova Mentis Life Science Corp. Auditor Raises 'Going Concern' Doubt	25-04-23
Nova Mentis Begins Recruitment in First-of-its-Kind Health Canada Psilocybin Trial	19-04-23
KGK Science Inc. Begins Recruitment in First-of-its-Kind Health Canada Approved Psilocybin Trial	18-04-23
KGK Sciences Inc. Begins Recruiting Participants, on Behalf of Client Nova Mentis Life Science Corp. in First-Ever Clinical Trial Investigating Effects of Psilocybin on Adults Diagnosed with Fragile X Syndrome	18-04-23
Nova Mentis Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial	12-04-23
Nova Mentis Life Science Corp. Receives Institutional Review Board Approval to Commence Psilocybin Clinical Trial	11-04-23
Nova Mentis Provides Corporate Update and 2023 Outlook	06-04-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Nova Mentis Life Science Corp.

Aandelen

NOVA

CA66980V1067

Andere talen

Filters